Journal
SIGNAL TRANSDUCTION AND TARGETED THERAPY
Volume 6, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41392-021-00658-5
Keywords
-
Categories
Funding
- Major International (Regional) Joint Research Program of the National Natural Science Foundation of China [81920108027]
- Chongqing Outstanding Youth Science Foundation
- Chongqing Talent Innovation Leader Project
- Funding for Chongqing University Innovation Research Group
Ask authors/readers for more resources
Inflammation plays a crucial role in cancer development and therapy, either promoting or inhibiting tumor progression and therapeutic outcomes. Various signaling pathways and factors have been identified as pivotal regulators of inflammation initiation and resolution.
Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Chronic inflammation facilitates tumor progression and treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation of dendritic cells (DCs) and antigen presentation, leading to anti-tumor immune responses. In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers and activators of transcription (JAK-STAT), toll-like receptor (TLR) pathways, cGAS/STING, and mitogen-activated protein kinase (MAPK); inflammatory factors, including cytokines (e.g., interleukin (IL), interferon (IFN), and tumor necrosis factor (TNF)-alpha), chemokines (e.g., C-C motif chemokine ligands (CCLs) and C-X-C motif chemokine ligands (CXCLs)), growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-beta), and inflammasome; as well as inflammatory metabolites including prostaglandins, leukotrienes, thromboxane, and specialized proresolving mediators (SPM), have been identified as pivotal regulators of the initiation and resolution of inflammation. Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, and SPM have been developed to specifically modulate inflammation in cancer therapy, with some of these factors already undergoing clinical trials. Herein, we discuss the initiation and resolution of inflammation, the crosstalk between tumor development and inflammatory processes. We also highlight potential targets for harnessing inflammation in the treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available